

PATHOLOGY GRAND ROUNDS



Markku M. Miettinen, MD

Head of Surgical Pathology
Laboratory of Pathology
National Cancer Institute/NIH

“New Soft Tissue Fusion Tumors - Diagnostic and Therapeutic Significance”

Thursday, November 21st, 2019

12:30 p.m.

Fitkin Amphitheater – LMP 1094

Host: William Laskin, MD



There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

NEEDS ASSESSMENT

There has been rapid development in the discovery of new gene fusions in soft tissue tumors due to advances in sequencing technology. In some cases, the detected fusion offers a new targeted therapy, such as kinase inhibitor drugs. The new fusion tumors and their diag-

nostic options are not well known. This lecture focuses on histopathologic, immunohistochemical, and genetic detection and confirmation for fusion tumors presenting in soft tissue. This knowledge may be important for application of the new fusion gene related targeted treatments.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Recognize histologically and immunohistochemically some of the new fusion tumors;
- Choose the best and cost-effective methods for fusion tumor diagnosis;

- Assist the clinical teams in finding treatment targets.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Speaker Name: Markku Miettinen, MD - NONE
Course Directors: Manju Prasad, MD - NONE
Kurt Schalper, MD, PhD - NONE
Gopal Pallavi, MD, PhD - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.